Discover
COLL
Collegium Pharmaceutical, Inc.
22.11
2 x 15.84
2 x 27.99
bid
ask
+
0.18
0.82%
2 @ 04:00 PM
22.11 +0.00 (0.00%)
| Ytd | -52.25% | |
| 1y | -33.26% |
21.79
day range
22.18
21.43
52 week range
50.79
| Open | 22.03 | Prev Close | 21.93 | Low | 21.79 | High | 22.18 | Mkt Cap | 719.80M |
| Vol | 532.92K | Avg Vol | 749.33K | EPS | 1.27 | P/E | 17.41 | Forward P/E | 4.86 |
| Beta | 0.73 | Short Ratio | 11.92 | Inst. Own | 128.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 25.65 | 200-d Avg | 35.21 | 1yr Est | 53.60 |
COLL News
zacks.com
New Strong Sell Stocks for October 7th
ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
globenewswire.com
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, Schoo
STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a
benzinga.com
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript
Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earni
benzinga.com
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price T
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) wit
benzinga.com
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49
Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with
benzinga.com
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Pr
Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL